Logo
x

Search category

Subscribe Now

US FDA Approval

The US FDA Approves New Indication for Lilly's Erbitux (cetuximab) + Braftovi (encorafenib) to Treat Metastatic Colorectal Cancer with a BRAF V600E Mutation

The US FDA Approves New Indication for Lilly's Erbitux (cetuximab) + Braftovi (encorafenib) to Treat Metastatic Colorectal Cancer...

  • September 29, 2021
GSK's Benlysta (belimumab) Receives the US FDA's Approval as the First Therapy for Active Lupus Nephritis (LN)

GSK's Benlysta (belimumab) Receives the US FDA's Approval as the First Therapy for Active Lupus Nephritis (LN)

  • December 18, 2020
Sedor's Sesquient Receives the US FDA's Approval for Status Epilepticus

Sedor's Sesquient Receives the US FDA's Approval for Status Epilepticus

  • November 9, 2020
Gilead's Veklury (remdesivir) Receives the US FDA's Approval as the First Treatment for COVID-19

Gilead's Veklury (remdesivir) Receives the US FDA's Approval as the First Treatment for COVID-19

  • October 23, 2020
AbbVie and Roche's Venclexta (venetoclax) Receive the US FDA's Approval for Acute Myeloid Leukemia

AbbVie and Roche's Venclexta (venetoclax) Receive the US FDA's Approval for Acute Myeloid Leukemia

  • October 19, 2020
BioMarin Receives the US FDA's Approval Allowing Maximum Dose of 60mg with Palynziq (pegvaliase-pqpz) for PKU

BioMarin Receives the US FDA's Approval Allowing Maximum Dose of 60mg with Palynziq (pegvaliase-pqpz) for PKU

  • October 8, 2020
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.